From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: NFX

Search articles by EPIC code

Nuformix – “unaudited” 12 months results, why the change in accounting reference date I wonder?!

Last week I wrote on pharmaceutical development company Nuformix (NFX) “absolutely delighted with the data we've generated”. Er, how’s the balance sheet now?”, concluding still a financial red flags fluttering Sell. What about now following “unaudited results for the twelve months ended 31 March 2023 following the change in the company's accounting reference date from 31 March to 30 September”?


Nuformix – “absolutely delighted with the data we've generated”. Er, how’s the balance sheet now?

Pharmaceutical development company Nuformix (NFX) has issued an “Inflammation and Duration of Action Update” on its 'NXP002' development programme, emphasising “absolutely delighted with the data we've generated over recent months - all the results we've achieved are as good as we could have hoped for and are the first results from advanced 'close to patient' IPF and inflammation human tissue disease models”. So what of a current share price response to 0.25p, down more than 7%?

Nuformix – interims, how’s the prior chaos now?

Previously writing on pharmaceutical development company Nuformix (NFX), in May with the shares falling below 0.50p I noted management chaos follows operational chaos, hopefully warnings heeded!. Co-founder and now again Executive Director Dan Gooding today though argues in half-year results, “I expect our on-going penultimate pre-clinical studies to conclude that our data and IP support the progression of the programme towards patients for whom I believe NXP002 can address both the side effect and efficacy limitations of existing IPF treatment options. We hope to announce results for both NXP002 and NX004 in the near-term”. So what of a 0.375p share price now?


Nuformix – “pleased to announce” a service contract, but why?...

Nuformix (NFX) “is pleased to announce that following the company's signing of an exclusive global licensing agreement with Oxilio Ltd for NXP001 on 13 September 2021, Oxilio has progressed the product and signed a significant service contract”. What though of a 29% share price rise in response, to 1.3p here?...


Nuformix – “delighted by the confidence shown by Lanstead”. Er...

“Subscription to raise £1.65 million”-titled announcement from pharmaceutical company Nuformix (NFX), with its Chairman Dr Alastair Riddell emphasising “delighted by the confidence shown by Lanstead in the future prospects of the company's products… products address large market opportunities. Importantly, this enables us to hire experienced business development expertise to build on our licensing opportunities for these products to pharmaceutical companies”. So why are the shares currently, at 1.20p, more than 14% lower?...

Page 1 of 2 (15 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments